NCT04819243View on ClinicalTrials.gov

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2027

Conditions
Premenopausal HR+/HER2- Metastatic Breast Cancer
Interventions
DRUG

Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab

"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib~* Atezolizumab"

DRUG

Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,

"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib"

Trial Locations (1)

06351

RECRUITING

Samsung medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER